R. Nakamura

发表

Feasibility and acceptability of utilizing a telehealth platform to monitor cardiovascular risk factors in hematopoietic cell transplant survivors at risk for cardiovascular disease.

B. Ky, Ellen K Chang, Aleksi Iukuridze, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene.

M. K. Magnússon, C. Dunbar, R. Nakamura, 2002, Blood.

Survival following allogeneic transplant in patients with myelofibrosis.

N. Kröger, M. Arcasoy, S. Verstovsek, 2020, Blood advances.

KIR2DS2 and KIR2DS4 promoter hypomethylation patterns in patients undergoing hematopoietic cell transplantation (HCT).

J. Zaia, S. Forman, D. Senitzer, 2012, Human immunology.

Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities.

N. Young, A. Barrett, J. Maciejewski, 2002, Blood.

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21).

C. Bloomfield, H. Deeg, K. Mrózek, 2021, Blood advances.

Large-scale manufacturing and characterization of CMV-CD19CAR T cells

Xiuli Wang, J. Zaia, S. Forman, 2022, Journal for ImmunoTherapy of Cancer.

Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine

Xiuli Wang, S. Forman, D. Diamond, 2021, International Journal of Hematology.

Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant.

G. Marcucci, I. Aldoss, S. Forman, 2021, Blood advances.

CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells

Xiuli Wang, J. Zaia, A. Mardiros, 2015, Clinical Cancer Research.

Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage-Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies.

G. Marcucci, I. Aldoss, S. Forman, 2021, Transplantation and cellular therapy.

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.

A. Logan, D. Miklos, M. Flowers, 2017, Blood.

Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease.

A. Nademanee, A. Krishnan, G. Somlo, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations.

D. Weisenburger, G. Marcucci, I. Aldoss, 2019, Clinical lymphoma, myeloma & leukemia.

Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation

S. Forman, D. Diamond, R. Nakamura, 2014, Bone Marrow Transplantation.

Ruxolitinib for the treatment of graft-versus-host disease

A. Salhotra, B. Modi, R. Nakamura, 2020, Expert review of clinical immunology.

Current Management and New Developments in the Treatment of Myelodysplastic Syndrome.

R. Nakamura, S. Khaled, Shukaib Arslan, 2021, Cancer treatment and research.

Decision Analysis of Transplantation for Patients with Myelodysplasia: “Who Should We Transplant Today?”

R. Nakamura, Shukaib Arslan, 2020, Current Hematologic Malignancy Reports.

Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improves Transplant Outcomes in Older MDS Patients.

M. Aljurf, J. Szer, R. Gale, 2021, Transplantation and cellular therapy.

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients.

R. Vij, W. Wood, M. Aljurf, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #110

E. Leifer, F. Appelbaum, M. Horowitz, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pharmacometabonomic association of cyclophosphamide 4‐hydroxylation in hematopoietic cell transplant recipients

B. Sandmaier, A. Karolak, D. Hockenbery, 2022, Clinical and translational science.

Transplant dose of CD34+ and CD3+ cells predicts outcome in patients with haematological malignancies undergoing T cell‐depleted peripheral blood stem cell transplants with delayed donor lymphocyte add‐back

R. Altemus, N. Young, A. Barrett, 2001, British journal of haematology.

relapsed non-Hodgkin lymphoma by autologous stem cell transplantation in patients with poor-risk or combination with high-dose etoposide and cyclophosphamide followed A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in

David D. Smith, A. Nademanee, A. Krishnan, 2013 .

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.

David D. Smith, A. Nademanee, A. Krishnan, 2005, Blood.

PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

P. Hari, S. Mineishi, P. Armand, 2017, Blood.

Ex vivo detection of CD8 T cells specific for H-Y minor histocompatibility antigens in allogeneic hematopoietic stem cell transplant recipients.

S. Forman, D. Senitzer, D. Diamond, 2014, Transplant immunology.

Protective Effect of HLA-DPB1 Mismatch Remains Valid in Reduced-Intensity Conditioning Unrelated Donor Hematopoietic Cell Transplantation

A. Nademanee, S. Forman, D. Snyder, 2019, Bone Marrow Transplantation.

ALTERATIONS IN INTESTINAL PERMEABILITY CAUSE COLONIC INFLAMMATION AND FIBROSIS IN TYPE III PHOSPHATIDYLINOSITOL PHOSPHATE KINASE-DEFICIENT MICE

Takehiko Sasaki, S. Takasuga, Y. Horie, 2014 .

Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.

B. Williams, J. Zaia, A. Krieg, 2012, The Journal of infectious diseases.

Severe Hyperglycemia Immediately After Allogeneic Hematopoietic Stem-Cell Transplantation is Predictive of Acute Graft-Versus-Host Disease

P. Parker, R. Nakamura, C. Behrendt, 2012, Inflammation.

Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity

Ubaydah Nasri, P. Martin, R. Nakamura, 2022, Frontiers in Immunology.

Ibrutinib for Chronic Graft-Versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.

A. Logan, D. Miklos, M. Flowers, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Expression of activating KIR2DS2 and KIR2DS4 genes after hematopoietic cell transplantation: relevance to cytomegalovirus infection.

J. Zaia, Lia Thao, S. Forman, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Expression of Activating KIR2DS2 and KIR2DS4 genes following hematopoietic cell transplant (HCT): relevance to cytomegalovirus (CMV) infection

J. Zaia, Lia Thao, D. Senitzer, 2011 .

Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myeloid leukemia.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.

Larry R. Smith, A. Wald, M. Boeckh, 2008, The Journal of infectious diseases.

Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study.

M. Boeckh, P. Southwick, J. Zaia, 2010, Blood.

Tissue-restricted T cell alloresponses across HLA barriers: selection and identification of leukemia-restricted CTL in HLA-mismatched stimulator–responder pairs

A. Barrett, N. Hensel, G. Sconocchia, 2003, Bone Marrow Transplantation.

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

R. Vij, M. Perales, F. Appelbaum, 2015, Blood.

The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis

R. Vij, Lixin Yang, M. Aljurf, 2022, Haematologica.

Tissue-resident PSGL1loCD4+ T cells promote B cell differentiation and chronic graft-versus-host-disease-associated autoimmunity.

A. Riggs, Xiwei Wu, K. Haas, 2020, The Journal of clinical investigation.

Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

G. Marcucci, S. Forman, S. Rahmanuddin, 2021, Blood advances.

HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome.

N. Young, A. Barrett, J. Maciejewski, 2002, Blood.

A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis

A. Barrett, D. Metcalfe, R. Childs, 2006, Bone Marrow Transplantation.

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.

Lixin Yang, G. Marcucci, I. Aldoss, 2019, Blood advances.

Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity

I. Aldoss, J. Zaia, S. Forman, 2022, Blood Advances.

Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

Y. Nieto, V. Bhatt, A. El-Jawahri, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Donor killer immunoglobulin-like receptor genes and reactivation of cytomegalovirus after HLA-matched hematopoietic stem-cell transplantation: HLA-C allotype is an essential cofactor

J. Zaia, S. Forman, R. Nakamura, 2013, Front. Immun..

Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation.

G. Marcucci, J. Zaia, S. Forman, 2019, Leukemia research.

A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome.

A. Barrett, Y. Saunthararajah, R. Nakamura, 2003, Blood.

Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.

A. Nademanee, S. Forman, A. Salhotra, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis

G. Marcucci, I. Aldoss, S. Forman, 2019, Bone Marrow Transplantation.

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

G. Marcucci, I. Aldoss, S. Forman, 2018, Haematologica.

Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome.

D. Follmann, N. Young, Y. Saunthararajah, 2001, Blood.

patients with myelodysplastic syndrome A simple method to predict response to immunosuppressive therapy in

A. Barrett, Y. Saunthararajah, R. Nakamura, 2013 .

Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process.

A. Barrett, Y. Saunthararajah, R. Nakamura, 2001, Leukemia research.

Venetoclax and hypomethylating agents in TP53‐mutated acute myeloid leukaemia

G. Marcucci, I. Aldoss, S. Forman, 2019, British journal of haematology.

Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia

G. Marcucci, I. Aldoss, S. Forman, 2021, British journal of haematology.

Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA‐Ven) or liposomal daunorubicin‐cytarabine (CPX‐351)

G. Marcucci, I. Aldoss, S. Forman, 2021, American journal of hematology.

Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS.

Y. Liu, M. Aljurf, J. Szer, 2020, Blood advances.

Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.

G. Marcucci, I. Aldoss, S. Forman, 2019, Blood advances.

Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia

G. Marcucci, I. Aldoss, P. Curtin, 2021, Cancer.

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia

I. Aldoss, S. Forman, D. Snyder, 2022 .

Long-term Outcomes of Allogeneic Hematopoietic Cell transplantation with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as GVHD prophylaxis in Patients with Acute Lymphoblastic Leukemia.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.

L. Pagano, M. Perales, I. Yakoub-Agha, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.

N. Kröger, E. Holler, Y. Efebera, 2018, Blood.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

N. Kröger, F. Locatelli, E. Holler, 2017, JCI insight.

Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation

N. Young, A. Barrett, R. Childs, 2003, Bone Marrow Transplantation.

Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia

G. Marcucci, I. Aldoss, S. Forman, 2020, American journal of hematology.

HLA‐DR4 predicts haematological response to cyclosporine in T‐large granular lymphocyte lymphoproliferative disorders

N. Young, A. Barrett, Y. Saunthararajah, 2003, British journal of haematology.

Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone.

M. Slovak, S. Forman, V. Bedell, 2007, Leukemia research.

Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria

R. Nakamura, 2016 .

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide

J. Wong, G. Marcucci, I. Aldoss, 2022, Blood advances.

Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study

J. Bolaños-Meade, Yi-Bin Chen, J. Hansen, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-Dose Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Patients with Poor-Risk or Relapsed Non-Hodgkin's Lymphoma (NHL)

David D. Smith, A. Nademanee, A. Krishnan, 2017 .

Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease.

K. Huelsman, S. Forman, R. Spielberger, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy.

J. Zaia, S. Forman, J. Rosenthal, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia

G. Marcucci, I. Aldoss, S. Forman, 2019, Bone Marrow Transplantation.

Response: Is CD103 a good surface marker for in vivo–activated effector/memory Treg cells in patients with chronic inflammation? Unknown yet

Dongchang Zhao, R. Nakamura, D. Zeng, 2009 .

Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).

G. Marcucci, I. Aldoss, P. Curtin, 2022, Leukemia & lymphoma.

Total Marrow and Lymphoid Irradiation with Post-Transplant Cyclophosphamide for Patients with AML in Remission.

J. Wong, E. Radany, G. Marcucci, 2022, Transplantation and cellular therapy.

Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation

Jeffery Y C Wong, G. Marcucci, I. Aldoss, 2021, Leukemia & lymphoma.

The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement

G. Marcucci, I. Aldoss, S. Forman, 2020, Leukemia & lymphoma.

Long term outcomes of patients with Acute Myeloid Leukemia treated with myeloablative FTBI based conditioning with Tacrolimus and sirolimus based GVHD prophylaxis regimen: 6 year follow up from Single Center.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

G. Marcucci, I. Aldoss, S. Forman, 2019, American journal of hematology.

T. Slavin, G. Marcucci, I. Aldoss, 2018, Haematologica.

Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

G. Marcucci, I. Aldoss, P. Curtin, 2022, Blood advances.

A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.

A. Nademanee, P. Frankel, S. Forman, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Overview of Hematopoietic Cell Transplantation

A. Salhotra, R. Nakamura, 2017 .

Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines.

M. Robin, G. Garcia-Manero, Z. DeFilipp, 2022, Transplantation and cellular therapy.

High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia.

N. Young, A. Barrett, A. Gratwohl, 2003, Blood.

Long-term follow up of patients with hematological malignancies treated with total body irradiation using intensity modulated radiation therapy

An Liu, J. Wong, S. Hui, 2022, Frontiers in Oncology.

Pathophysiology and Immunology of Chronic Graft-Versus-Host Disease

A. Salhotra, R. Nakamura, 2017 .

Feasibility of geriatric assessment before transplant conditioning regimen in older HCT recipients

M. Sorror, J. McCune, S. Armenian, 2020, Bone Marrow Transplantation.

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.

S. Grupp, D. Porter, M. Pasquini, 2014, Blood.

A Phase 2 Study of F-652, a Novel Tissue-Targeted Recombinant Human Interleukin-22 (IL-22) Dimer, for Treatment of Newly Diagnosed Acute Gvhd of the Lower GI Tract

M. V. D. van den Brink, J. Shia, A. Alousi, 2020 .

Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402

S. Grupp, D. Porter, M. Pasquini, 2012 .

Red blood cell and platelet transfusion support in the first 30 and 100 days after allogeneic hematopoietic cell transplant

C. Karanes, R. Nakamura, Shan Yuan, 2020, Transfusion.

Dasatinib-Induced Colitis after Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

I. Aldoss, S. Forman, V. Pullarkat, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation

G. Marcucci, I. Aldoss, S. Forman, 2021, Bone Marrow Transplantation.

Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation.

L. Jones, S. Forman, Jessica M. Scott, 2019, Journal of the National Cancer Institute.

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

R. Vij, M. Perales, F. Appelbaum, 2015, Blood.

Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis

S. Forman, R. Nakamura, 2014, Expert review of hematology.

Late‐occurring infections in a contemporary cohort of hematopoietic cell transplantation survivors

S. Armenian, Sanjeet S. Dadwal, F. L. Wong, 2020, Cancer medicine.

The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future.

W. Wood, P. Chiusolo, R. Storb, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug‐drug interaction study

D. Pon, Sanjeet S. Dadwal, R. Nakamura, 2018, Transplant infectious disease : an official journal of the Transplantation Society.

High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation

S. Solomon, R. Childs, R. Nakamura, 2002, Bone Marrow Transplantation.

Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients.

J. Zaia, Lia Thao, S. Forman, 2008, Blood.

Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis.

P. Wallace, P. McCarthy, T. Hahn, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

RBC and platelet transfusion support in the first 30 and 100 days after haploidentical hematopoietic stem cell transplantation

R. Nakamura, Shan Yuan, Dongyun Yang, 2019, Transfusion.

Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients

G. Marcucci, S. Forman, R. Nakamura, 2021, Transplantation and Cellular Therapy.

Molecular and flow cytometric characterization of the CD4 and CD8 T‐cell repertoire in patients with myelodysplastic syndrome

D. Follmann, J. Melenhorst, A. Barrett, 2002, British journal of haematology.

Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

R. Vij, B. Sandmaier, M. Aljurf, 2019, Haematologica.

Hematopoietic Cell Transplantation

S. Forman, Stephen J. Forman, Ryotaro Nakamura, 2015 .

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide.

Shannon R. McCurdy, M. Perales, R. Soiffer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia.

An Liu, T. Schultheiss, J. Wong, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

SARS-CoV-2 Specific Monoclonal Antibody for the Treatment of Mild-to-Moderate COVID-19 in Cancer Patients: A Single-center Experience

P. Frankel, R. Taplitz, D. Nanayakkara, 2021, Journal of Infectious Diseases.

Changes in T-cell receptor VB repertoire in aplastic anemia: effects of different immunosuppressive regimens.

N. Young, M. Wlodarski, J. Maciejewski, 2002, Blood.

Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.

A. Nademanee, A. Krishnan, S. Forman, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical HCT with Post-Transplant Cyclophosphamide

G. Marcucci, J. Pidala, S. Forman, 2021, Transplantation and Cellular Therapy.

Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.

E. Leifer, H. Deeg, J. Tolar, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib

G. Marcucci, R. Nakamura, H. Ali, 2022, Bone Marrow Transplantation.

Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates.

David D. Smith, S. Forman, D. Senitzer, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.

N. Young, J. Maciejewski, L. Luzzatto, 2006, The New England journal of medicine.

Lipidomics of cyclophosphamide 4‐hydroxylation in patients receiving post‐transplant cyclophosphamide

B. Sandmaier, D. Hockenbery, T. Randolph, 2022, Clinical and translational science.

Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA Mismatch

A. Nademanee, S. Forman, D. Snyder, 2020, Transplantation.

Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS).

J. Cortes, M. Horowitz, M. Kalaycio, 2013, Blood.

A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection

J. Zaia, D. Diamond, Sanjeet S. Dadwal, 2018, Expert review of vaccines.

Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.

E. Leifer, H. Deeg, M. Horowitz, 2015, The Lancet. Haematology.

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

B. Sandmaier, M. Aljurf, R. Gale, 2019, Blood advances.

Evaluation of elafin as a prognostic biomarker in acute graft-versus-host disease.

S. Grupp, Yi-Bin Chen, Z. DeFilipp, 2021, Transplantation and cellular therapy.

Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin.

E. Holler, Yi-Bin Chen, Z. DeFilipp, 2020, Blood advances.

Disease Risk and GVHD Biomarkers Can Stratify Patients For Risk of Relapse and Non-Relapse Mortality Post Hematopoietic Cell Transplant

N. Kröger, Yi-Bin Chen, M. Qayed, 2020, Leukemia.

Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.

J. Weitzel, S. Forman, J. Herzog, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Influence of Drug Absorption, Distribution, Metabolism, and Excretion (ADME) Variants on Sirolimus Blood Levels in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation

S. Forman, J. Herzog, D. Senitzer, 2013 .

Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis.

S. Forman, P. Parker, R. Nakamura, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation–Associated Thrombotic Microangiopathy

Y. Kwong, N. Nangia, A. Rambaldi, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis

I. Yakoub-Agha, D. Mclornan, A. Radujkovic, 2022, British journal of haematology.

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Hematopoietic Cell Transplantation, Version 2.2020

Y. Nieto, V. Bhatt, A. El-Jawahri, 2020 .

Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia

H. Deeg, M. Ayas, M. Pulsipher, 2014, Haematologica.

Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation.

A. Ganser, M. Labopin, A. Nagler, 2020, Blood advances.

Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones.

I. Aldoss, S. Forman, D. Snyder, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia

An Liu, J. Wong, G. Marcucci, 2022, Frontiers in Oncology.

Flow cytometric quantitation and characterization of the T-lymphocyte memory response to CMV in healthy donors.

A. Barrett, N. Hensel, A. Schwarer, 2002, Cytotherapy.

Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.

D. Follmann, A. Barrett, N. Hensel, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.

S. Forman, D. Snyder, V. Pullarkat, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab

A. Risitano, G. Khursigara, A. Gaya, 2010, British journal of haematology.

Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome

E. Leifer, P. Westervelt, F. Appelbaum, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

E. Leifer, P. Westervelt, F. Appelbaum, 2020, Transplantation and Cellular Therapy.

Cytokine gene polymorphisms are associated with response to blinatumomab in B‐cell acute lymphoblastic leukemia

Xiwei Wu, G. Marcucci, Wei Chen, 2021, European journal of haematology.

A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease

A. Salhotra, B. Modi, R. Nakamura, 2022, Expert review of clinical immunology.

MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults.

I. Aldoss, J. Zaia, J. Longmate, 2017, Blood.

Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients

A. Nademanee, I. Aldoss, S. Forman, 2020, Annals of Internal Medicine.

A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.

A. Krishnan, S. Forman, D. Senitzer, 2010, Blood.

Thymoglobulin, CYA and mycophenolate mofetil as GVHD prophylaxis for reduced-intensity unrelated donor hematopoietic cell transplantation: beneficial effect seen on chronic GVHD

S. Forman, D. Senitzer, D. Snyder, 2010, Bone Marrow Transplantation.

Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome

M. Slovak, S. Forman, R. Bhatia, 2007, Bone Marrow Transplantation.

Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation

T. Slavin, L. Jones, S. Forman, 2020, Journal of cachexia, sarcopenia and muscle.

Clinical and immunologic responses to extracorporeal photopheresis and low-dose IL-2 in patients with steroid refractory chronic graft-versus host disease

Xiwei Wu, I. Aldoss, A. Salhotra, 2022, Bone Marrow Transplantation.

A multicenter open-label phase 1b/2 study of ibrutinib in steroid dependent or refractory chronic graft versus host disease (cGVHD).

D. Miklos, M. Arora, S. Jaglowski, 2015 .

Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

S. Forman, S. Armenian, F. L. Wong, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.

I. Aldoss, J. Longmate, D. Diamond, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.

I. Aldoss, J. Longmate, D. Diamond, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial.

I. Aldoss, Jeffrey S. Miller, J. Zaia, 2016, The Lancet. Haematology.

Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy.

R. Vij, P. McCarthy, B. Logan, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids

A. Logan, D. Miklos, M. Flowers, 2016 .

Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia

J. Zaia, J. Ito, J. Kriengkauykiat, 2019, Transplant infectious disease : an official journal of the Transplantation Society.

Cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic hematopoietic stem cell transplantation: viremia, immunogenicity and survival outcomes in a randomised phase 1b trial

I. Aldoss, Jeffrey S. Miller, J. Zaia, 2015, The Lancet. Haematology.

Hematopoietic stem cell donor vaccination with cytomegalovirus triplex augments frequencies of functional and durable cytomegalovirus‐specific T cells in the recipient: A novel strategy to limit antiviral prophylaxis

I. Aldoss, D. Diamond, A. Artz, 2023, American journal of hematology.

Institution affects association between CMV seronegative graft and leukemic relapse after pediatric HCT.

J. Zaia, R. Nakamura, C. Behrendt, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Post-transplant sinusoidal obstruction syndrome in adult patients with B-cell Acute Lymphoblastic Leukemia treated with pre-transplant Inotuzumab.

G. Marcucci, I. Aldoss, P. Curtin, 2023, Transplantation and cellular therapy.

Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study

M. Perales, S. Putta, W. Saber, 2022, Transplantation and cellular therapy.

Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.

P. Westervelt, M. Pasquini, M. Horowitz, 2014, Blood.

Germline predisposition variants occur in myelodysplastic syndrome patients of all ages.

S. Spellman, R. Sobecks, L. Godley, 2022, Blood.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in T-cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.

J Wagner, F. Awan, M. Krem, 2022, Transplantation and cellular therapy.

Conditional Survival, Cause-specific Mortality, Risk Factors of Late Mortality After Allogeneic Hematopoietic Cell Transplantation.

S. Forman, Heeyoung Kim, S. Armenian, 2020, Journal of the National Cancer Institute.

Tacrolimus initial steady state level in post-transplant cyclophosphamide based GvHD prophylaxis regimens

G. Marcucci, I. Aldoss, S. Forman, 2021, Bone Marrow Transplantation.

Prediction of cardiovascular disease among hematopoietic cell transplantation survivors.

W. Leisenring, E. Chow, S. Forman, 2018, Blood advances.

Impact of Genetic Mutations on the Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia with Antecedent Myeloproliferative Neoplasm

U. Popat, J. Capo-Chichi, K. Ahn, 2020 .

Priorities for Improving Outcomes for Non-Malignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network.

H. Heslop, S. Devine, G. Yanik, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase 2 study of Interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract.

M. Perales, M. V. D. van den Brink, S. Devlin, 2022, Blood.

Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation

H. Deeg, J. Kurtzberg, M. Ayas, 2014, Haematologica.

Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide

Shannon R. McCurdy, M. Perales, M. Horowitz, 2016 .

Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

A. Nademanee, G. Marcucci, S. Forman, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.

H. Deeg, M. Perales, H. Kluin-Nelemans, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors.

R. Vij, M. Aljurf, R. Gale, 2022, JAMA oncology.

Incidence and Risk Factors for de novo Cutaneous Squamous Cell Carcinoma in a Contemporary Cohort of Long-term Hematopoietic Cell Transplantation Survivors.

A. Geller, S. Forman, S. Armenian, 2021, The Journal of investigative dermatology.

Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH)

A. Marghoob, K. Emmons, C. Coleman, 2020, BMC Cancer.

Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia.

I. Aldoss, S. Forman, D. Snyder, 2016, Clinical lymphoma, myeloma & leukemia.

Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors.

B. George, M. Grunwald, D. Weisdorf, 2021, Blood advances.

Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.

B. Sandmaier, M. Perales, A. Nagler, 2020, Blood advances.

A Phase II Trial of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation

A. Nademanee, G. Marcucci, I. Aldoss, 2020 .

The Use of Sirolimus Combined with Tacrolimus and Low-Dose Methotrexate Is Effective in Preventing Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation.

A. Nademanee, S. Forman, D. Senitzer, 2006 .

Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status

D. Weisenburger, G. Marcucci, I. Aldoss, 2017, Haematologica.

Aprepitant (Emend) significantly increases sirolimus levels in patients undergoing allogeneic hematopoietic SCT

S. Forman, V. Pullarkat, A. Nademanee, 2012, Bone Marrow Transplantation.

A phase II study of sirolimus, tacrolimus, and rabbit anti-thymocyte globulin as graft-versus-host prophylaxis after unrelated-donor peripheral blood stem cell transplant

A. Nademanee, S. Forman, D. Senitzer, 2012, Bone Marrow Transplantation.

Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis.

K. Chang, S. Forman, J. Alvarnas, 2012, Leukemia research.

Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation

S. Forman, A. Salhotra, R. Nakamura, 2015, Bone Marrow Transplantation.

Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study

G. Marcucci, I. Aldoss, S. Forman, 2023, Frontiers in Immunology.

NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022.

J. Bolaños-Meade, Y. Nieto, A. El-Jawahri, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Effect of the Terminal Complement Inhibitor Eculizumab on Patient Reported Outcomes in Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase III Triumph Study Results.

D. Cella, A. Zanella, U. Dührsen, 2006 .

Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial

G. Marcucci, I. Aldoss, S. Forman, 2020 .

Tacrolimus and Sirolimus as GVHD Prophylaxis for Sibling Donor Hematopoietic Stem Cell Transplant (HCT) Using Three Conditioning Regimens; Fludarabine-Melphalan, FTBI-VP16, and Busulfan-Cyclophosphamide

S. Forman, D. Senitzer, D. Snyder, 2009 .

Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis

G. Marcucci, I. Aldoss, S. Forman, 2019, Blood.

Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes

Lixin Yang, G. Marcucci, I. Aldoss, 2021, Blood Cancer Journal.

Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT.

G. Marcucci, I. Aldoss, S. Forman, 2021, Leukemia research.

Iron Overload is Associated with Delayed Engraftment and Increased Non-Relapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation.

A. Nademanee, G. Marcucci, I. Aldoss, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prediction of Acute Graft versus Host Disease and Relapse by Endogenous Metabolomic Compounds in Patients Receiving Personalized Busulfan-Based Conditioning.

H. Deeg, A. Huitema, E. V. van Maarseveen, 2020, Journal of proteome research.

Remission Induction in a Phase I/II Study of an Anti-CD20-Interleukin-2 Immunocytokine DI-Leu16-IL2 in Patients with Relapsed B-Cell Lymphoma

S. Gillies, V. Bachanova, F. Lansigan, 2015 .

INPP4B Is a PtdIns(3,4,5)P3 Phosphatase That Can Act as a Tumor Suppressor.

H. Nakanishi, T. Habuchi, A. Suzuki, 2015, Cancer discovery.

High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia‐like fusions

G. Marcucci, I. Aldoss, P. Curtin, 2023, American journal of hematology.

Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease

P. Hari, P. Armand, L. Andritsos, 2016 .

Immunosuppressant adherence in adult outpatient hematopoietic cell transplant recipients.

D. Mager, Wei Gao, J. McCune, 2023, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Acute leukemia and myelodysplasia after adjuvant chemotherapy for breast cancer: durable remissions after hematopoietic stem cell transplantation.

S. Bhatia, G. Somlo, V. Bedell, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A Multi-Center, Randomized, Double Blind, Phase III Clinical Trial Comparing Steroids/Placebo Vs. Steroids/Mycophenolate Mofetil As Initial Therapy for Acute Graft-Versus-Host Disease. Blood and Marrow Transplant Clinical Trials Network Study 0802

P. Westervelt, M. Pasquini, M. Horowitz, 2013 .

Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation

S. Forman, Heeyoung Kim, S. Armenian, 2019, Bone Marrow Transplantation.

The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study

G. Marcucci, S. Forman, R. Nakamura, 2023, Stem cell research & therapeutics.

Philadelphia chromosome as a recurrent event among therapy‐related acute leukemia

G. Marcucci, I. Aldoss, S. Forman, 2017, American journal of hematology.

Management of Drug Interaction between Posaconazole and Sirolimus in Patients Who Undergo Hematopoietic Stem Cell Transplant

H. Nguyen, D. Pon, R. Nakamura, 2015, Pharmacotherapy.

Feasibility of implementing a supervised telehealth exercise intervention in frail survivors of hematopoietic cell transplantation: a pilot randomized trial

Kyuwan Lee, S. Forman, L. Hageman, 2023, BMC Cancer.

Acute Gvhd Diagnosis and Adjudication in a Multicenter Trial – a Report from the BMT CTN 1202 Biorepository Study

Yi-Bin Chen, J. Hansen, W. Saber, 2019, Biology of Blood and Marrow Transplantation.

Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma.

A. Nademanee, S. Forman, R. Spielberger, 2023, Clinical lymphoma, myeloma & leukemia.

Severe Hyperglycemia Immediately After Allogeneic Hematopoietic Stem-Cell Transplantation is Predictive of Acute Graft-Versus-Host Disease

P. Parker, R. Nakamura, C. Behrendt, 2013, Inflammation.

Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes

A. Nademanee, G. Marcucci, I. Aldoss, 2018, Blood.

Tocilizumab for Cytokine Release Syndrome Management after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.

G. Marcucci, I. Aldoss, P. Curtin, 2023, Transplantation and cellular therapy.

Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma

A. Krishnan, P. Frankel, G. Somlo, 2006, Bone Marrow Transplantation.

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

S. Forman, T. Synold, D. Snyder, 2019, Blood.

SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study

M. Dhodapkar, P. Westervelt, M. Perales, 2023, eClinicalMedicine.

Stephanie J. Lee, B. Shaw, K. Flynn, 2022, American journal of hematology.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

N. Kröger, F. Locatelli, E. Holler, 2018, JCI insight.

Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias

G. Marcucci, I. Aldoss, A. Salhotra, 2021, Blood.

DETECTION OF EPSTEIN‐BARR VIRAL DNA IN AGGRESSIVE CD8+ T CELL LEUKAEMIC CELLS

S. Matsushita, K. Takatsuki, N. Asou, 1992, British journal of haematology.

Association of pre-transplant vancomycin resistant enterococcus colonization status on long-term outcomes of allogeneic-hematopoietic cell transplantation

S. Forman, A. Artz, R. Spielberger, 2022, Bone Marrow Transplantation.

Detection and preliminary characterization of CD8+T lymphocytes specific for Wilms’ tumor antigen in patients with non-Hodgkin lymphoma

A. Rosenwald, J. Zaia, S. Forman, 2013, Leukemia & lymphoma.

Immune monitoring with iTAg™ MHC tetramers for prediction of recurrent or persistent cytomegalovirus (CMV) infection in allogeneic stem cell transplant (SCT) recipients: A prospective multicenter clinical trial

M. Boeckh, J. Gratama, P. Southwick, 2006 .

Trafficking between clonally related peripheral T helper cells and tissue-resident T helper cells in chronic GVHD.

Xiwei Wu, Ubaydah Nasri, A. Salhotra, 2022, Blood.

Social vulnerability and risk of non-relapse mortality after allogeneic hematopoietic cell transplantation.

Marta M. Jankowska, S. Forman, A. Artz, 2022, Journal of the National Cancer Institute.

Association Between Body Composition and Development of Glucose Intolerance after Allogeneic Hematopoietic Cell Transplantation.

Kyuwan Lee, S. Armenian, S. Mostoufi-Moab, 2022, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

1 INPP 4 B is a PtdIns ( 3 , 4 , 5 ) P 3 phosphatase that can act as a tumor suppressor

H. Nakanishi, T. Habuchi, A. Suzuki, 2015 .

Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations

G. Marcucci, I. Aldoss, S. Forman, 2022, Blood.

Tacrolimus and Sirolimus as GVHD Prophylaxis for HLA-MRD Allogeneic HCT Conditioned with 3 Regimens: Toxicity and Efficacy in 70 Patients.

A. Nademanee, S. Forman, D. Senitzer, 2006 .

Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

S. Grupp, E. Holler, Z. DeFilipp, 2023, Blood advances.

High prevalence and inferior long‐term outcomes for TP53 mutations in therapy‐related acute lymphoblastic leukemia

G. Marcucci, I. Aldoss, P. Curtin, 2022, American journal of hematology.

A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

I. Yakoub-Agha, M. Aljurf, R. Gale, 2023, Blood advances.

The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future.

W. Wood, P. Chiusolo, R. Storb, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.

Larry R. Smith, A. Wald, M. Boeckh, 2008, The Journal of infectious diseases.

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.

A. Logan, D. Miklos, M. Flowers, 2017, Blood.

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

B. Sandmaier, M. Aljurf, R. Gale, 2019, Blood advances.

Running Title: Haploidentical vs. Unrelated Donor Transplant

M. Horowitz, P. Armand, S. Devine, 2015 .

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

R. Vij, M. Perales, F. Appelbaum, 2015, Blood.

Survival after T-Cell Replete Haplo-Identical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor Transplant for Acute Myeloid Leukemia

R. Vij, M. Perales, F. Appelbaum, 2014 .

B. Sandmaier, M. Aljurf, M. Grunwald, 2019, Haematologica.

A review of low dose interleukin-2 therapy in management of chronic graft-versus-host-disease.

A. Salhotra, B. Modi, R. Nakamura, 2023, Expert review of clinical immunology.

Thrombotic Microangiopathy After Hematopoietic Stem Cell and Solid Organ Transplantation: A Review for Intensive Care Physicians.

R. Nakamura, K. MacDougall, A. Borogovac, 2023, Journal of intensive care medicine.

Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102

L. Steuten, P. Westervelt, J. Pidala, 2024, JCO oncology practice.